D
iabetic retinopathy is a serious complication of diabetes and can have severe debilitating effects on lifestyle, work and relationships. In the UK diabetic retinopathy remains the main cause of visual impairment and registered blindness in people under 65 years of age (Bunce and Wormald, 2006; Kumar et al, 2006) . This is despite evidence that 60-80% of visual loss is preventable by laser treatment (Dineen et al, 2008) .
To be effective treatment for retinopathy needs to be given at the appropriate stage of the disease, often before symptoms have developed; thus the importance of screening to detect the signs of retinopathy before they progress (Arun et al. 2005) .
The prevalence and incidence of type 1 and type 2 diabetes continues to rise, although type 2 diabetes may be preventable in many cases (Amos et al, 1997; Yorkshire and Humberside Public Health Observatory, 2009; Tuomilehto et al, 2001) . Data from large studies of the microvascular complications of diabetes, demonstrate that diabetic retinopathy can be prevented and managed effectively through good management (Diabetes 
Progression of retinopathy
In diabetes there is considerable fluctuation in the blood glucose levels and abnormally high levels have an effect on the small blood vessels (capillaries) of the eyes, kidneys and those that feed the nerves. As a result, the capillary wall becomes thickened in small areas and forms microaneursyms, which eventually burst, causing haemorrhage.
If enough of this abnormal physiology occurs, the organs affected do not receive enough blood supply to function properly, which leads to triggering of ischaemic and scarring responses.
Diabetic retinopathy is a progressive disease and is
Background retinopathy
The term 'background retinopathy' is used to describe the appearance of microanuerysms and haemorrhages on fundus examination, commonly termed 'dot and blot haemorrhages' (Figure 2) .
It is important to consider what having background retinopathy means for the person with diabetes.
Background retinopathy will not result in visual symptoms. However, it is important to consider how effectively the patient is managing his/her diabetes by monitoring HbA 1c and blood pressure levels. A lifestyle or treatment change may be Pre-proliferative retinopathy presents with no visual symptoms, but is considered hazardous and a precursor to more severe sight-threatening eye disease. Pre-proliferative retinopathy is divided into mild, moderate and severe, indicating a progression toward proliferation.
Practice indicators
➤ Review patient management and shared care plan-consider changes to improve control ➤ The patient needs to be under regular (3-6 months) ophthalmology service review.
➤ Check that the retinopathy
level is recorded on the patient record data system.
Proliferative retinopathy
Proliferative retinopathy is the manifestation of neovascular growth either in the peripheral fundus or at the optic disc ( Figure 3 ). This occurs when retinal blood supply is no longer sufficient, resulting in abnormal vessel growth. These new vessels, however, are fragile and do not follow normal anatomical routes. They are prone to bleed, causing pre-retinal haemorrhage or vitreous haemorrhage. Visual loss may be complete or partial in the affected eye. However, before this occurs the patient may not experience any symptoms, unaware that severe sight threatening eye disease has developed.
Until the blood vessels bleed the patient may be unaware that he/she has sightthreatening eye disease, as there may be no visual symptoms.
Practice indicators
➤ If proliferative retinopathy is picked up by screening, the patient should be referred urgently for laser treatment by ophthalmology services. Laser treatment is the intervention that prevents partial sight registration and blindness in diabetes. It is highly effective working in up to 90% of patients (Dineen et al, 2008 
Maculopathy
One further classification is used in the detection of diabetic retinopathy. Maculopathy is the manifestation of diabetic retinopathy which occurs in the macular area of the fundus, which is used for detailed vision. Signs of maculopathy are exudates and clinically significant macular oedema. Oedema is sight threatening and is usually manifest to the patient as blurred vision. It can only be detected by stereoscopic examination of the fundus.
Health education
Health education is a vital strategy which can empower patients to seek annual eye checks and give patients the encouragement and knowledge to take control of their diabetes by following a healthy lifestyle.
Health education is necessary but must be tailored to individuals' needs in the context of their particular lifestyle with the differing coping and cognitive mechanisms considered, i.e. a psycho-educational approach (Duke et al 2009 
Current NHS Policy
The NSPDR (2008) 
Patient experience
It is important to consider the patient's experience and the benefits of attending the screening programme. There have been some attempts in the literature to explore reasons for non-attendance to screening which have revealed; fear, lack of knowledge, economics, poor access; social deprivation; duration of diabetes; and equity (Gillibrand et al. 2000a; 2001; Hartnett et al, 2005; Millett and Dodhia, 2006; Leese et al, 2008) .
Methods to improve attendance have focused on group education sessions using local networks, culturally sensitive education, accessibility, and conducting regular equity audits (Livingston et al, 1998; Gillibrand et al, 2000b; Millett and Dodhia, 2006 (DCCT, 1993; UKPDS, 1998) .
Therefore if people with diabetes can maintain stable blood glucose levels they will be more likely not to develop complications and will reduce the severity. The practice nurse has an important role in educating patients about diabetic retinopathy, to ensure that all their patients attend annual retinopathy screening, and provide diabetes management support, to prevent complications of diabetes developing. Michael is a 56-year-old married man, with two children. He was diagnosed with type 2 diabetes 8 years ago after a visit to the GP with symptoms of polyuria and fatigue. confirmed by a fasting blood glucose test. He managed well for a short time on a diet and exercise regimen, but owing to weight gain and a rise in glycated haemoglobin (HbA 1c ), to 70 mmol/mol (8.6%), he started on metformin. His blood pressure is 152/86 mmHg (150/88 mmHg on last recording) but he is not currently receiving any treatment for this.
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Recently Michael was invited to attended the optician for an annual retinopathy screening examination. He was sent a letter, co-ordinated by the PCT, which informed him about the screening and advised that he should not drive to and from the optician. At the examination, Michael was given an explanation of the procedure by the retinal screener and invited to ask questions. The screening assessment began with a check of Michael's visual acuity, as some forms of retinopathy can affect vision in the early stages. His pupils were then dilated using tropicamide 1%. The National Screening Programme for Diabetic Retinopathy (2008) recommends tropicamide 1% eye drops as the most effective for pupil dilation for fundus photography and the least likely to
CASE STuDy cause adverse reactions).
After the pupils were dilated, a number of digital images were taken of each fundus and stored on the computer for later grading of retinopathy by the screener. Two weeks later, Michael received a letter from his general practice stating that preproliferative retinopathy had been detected. He was referred to ophthalmology at the local hospital. At the hospital, a detailed examination was carried out, and the consultant ophthalmologist recommended a 6-month follow-up to monitor progress.
Michael also attended a consultation with the practice nurse at his health centre, where an agreed shared care plan was devised, with the main goal to help Michael do more exercise, reduce his weight and improve his glycaemic control. The nurse discussed a blood pressure target of 130/80 mmHg.
Following NICE guidance (2008) she recommended an ACE inhibitor (enalapril 5 mg) following a check of his renal function and electrolytes. In follow-up checks his dose was titrated to 20 mg daily. Michael's HbA 1c fell to 62 mmol/mol (7.8%) and his blood pressure was 136/82 mmHg at the ophthalmologist review, the pre-proliferative signs had reduced, with no progression to the proliferative stage.
